RNA-seq of breast cancer cell lines post ligand treatment II

Goal: study the impact of estrogen receptor ligands on gene expression in HR+ breast cancer cells Methods: RNA sequencing Results: Ligand 4-OH tamoxifen, a selective ER modulator (SERM), promotes transcriptional activation of ER and mimics the transcriptional effect of natural ligand E2 for a subset of ER target genes, consistently across the seven breast cell lines (MDA-MB-134 VI, MDA-MB-330, EFM-19, T-47D, and BT-474). Selective ER degraders (SERD) fulvestrant and GDC-0927 on the other hand do not induce, or induce very weakly the expression of ER target genes. The effect of GDC-0810 depends on the cellular context. Overall design: Duplicates results of RNA-Seq of seven cell lines treated with six different estrogen receptor ligands or DMSO for 24 hours

研究目标：探究雌激素受体配体对激素受体阳性（HR+）乳腺癌细胞基因表达的影响。
实验方法：采用RNA测序（RNA-seq）技术。
实验结果：配体4-羟基他莫昔芬（4-OH tamoxifen）作为选择性雌激素受体调节剂（selective ER modulator, SERM），可促进雌激素受体（estrogen receptor, ER）的转录激活，并在部分雌激素受体靶基因上模拟天然配体雌二醇（estradiol, E2）的转录效应，该效应在7种乳腺癌细胞系（MDA-MB-134 VI、MDA-MB-330、EFM-19、T-47D及BT-474）中均保持一致。与之相反，选择性雌激素受体降解剂（selective ER degrader, SERD）氟维司群（fulvestrant）与GDC-0927既无法诱导雌激素受体靶基因的表达，仅能产生极微弱的诱导效果。而GDC-0810的调控效应则依赖于细胞微环境。
整体实验设计：针对经6种不同雌激素受体配体或二甲基亚砜（DMSO）处理24小时的7种细胞系，开展RNA测序的重复实验。